HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
Stocks · News reference
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Cardiff Oncology, Inc. (CRDF)
Filed: 2026-09-14 AccNo: 0001493152-26-042506 Size: 370 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Cardiff Oncology Announces Settlement With Nerviano Medical Sciences And Amended 2017 Onvansertib License Agreement, Resolving All Litigation; Parties To Seek Dismissal With Prejudice
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.